查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854533

MRI造影劑市場按產品類型、藥物類別、應用、最終用途、分銷管道和給藥途徑分類－2025-2032年全球預測

MRI Contrast Media Agents Market by Product Type, Agent Class, Application, End Use, Distribution Channel, Administration Route - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，MRI造影劑市場規模將達到 48.9 億美元，複合年成長率為 7.83%。

主要市場統計數據
基準年 2024 26.7億美元
預計年份：2025年 28.8億美元
預測年份：2032年 48.9億美元
複合年成長率 (%) 7.83%

本書權威地介紹了磁振造影造影劑，闡述了其化學多樣性、臨床效用以及安全性造影產品開發和臨床應用的重要性。

磁振造影造影劑是現代影像的關鍵，它們能夠增強組織對比度，並使各種臨床適應症的影像解讀更加可靠。钆基對比劑長期以來在許多診斷流程中佔據主導地位，而鐵基和錳基對比劑則是為了滿足特定的安全性和成像目標而設計的。製劑特性，包括化學性質和分子結構（例如，钆配合物的離子型與非離子型，以及鎖狀與大環結構） ，都會影響其臨床性能和安全性。

臨床效用涵蓋腹部、心血管系統、中樞神經系統和肌肉骨骼系統的成像，對弛豫率、生物分佈和清除率的要求各不相同。因此，相關人員必須權衡診斷獲益與不斷更新的安全證據和監管指南。近年來，人們對钆組織滯留以及易感患者發生腎源性系統性纖維化的風險日益關注，促使人們不斷創新並重新評估低劑量製劑方案。因此，現代造影劑的應用不僅要關注其藥理學和物理化學特性，還要關注新興的臨床最佳實踐、風險緩解策略以及影響產品供應和標籤的法規環境。

這些方向為策略分析奠定了基礎。製造商、臨床醫生和採購負責人將受益於對分子設計、給藥途徑和最終用途如何共同決定臨床應用、安全監測和商業性可行性的清晰理解。隨著影像生態系統的演變，這種基本觀點使相關人員能夠預測整個產業和醫療保健服務體系中產品偏好、投資重點和合作管道的變化。

安全審查、影像技術進步和監管結構調整如何推動MRI造影劑創新和應用領域的策略轉變

磁振造影造影劑領域正經歷著變革性的轉變，其驅動力來自多方面因素：日益嚴格的安全審查、影像處理通訊協定的進步以及監管和採購環境的重組。安全性問題，尤其是钆滯留相關的問題，促使人們對大環螯合物產生了濃厚的興趣。與鎖狀螯合物相比，大環螯合物具有更高的動力學穩定性，並在許多臨床領域中逐漸成為首選方案。同時，創新範圍已從钆擴展到鐵基和錳基對比劑，旨在平衡診斷性能與差異化的安全性和藥物動力學特性。

同時，磁振造影硬體和序列設計的改進正在改變對造影劑的需求。高場強掃描儀、定量成像生物標記和人工智慧驅動的後處理有望提高靈敏度並減少對高劑量造影的依賴。這些技術進步促使生產者和臨床團隊重新評估給藥策略，並開發針對特定影像模式最佳化的造影劑。監管機構也做出了回應，發布了更詳細的附加檔、風險溝通和上市後監測指南，鼓勵生產商投資長期安全性測試並加強藥物安全檢測系統。

從商業性角度來看，這種轉變正在推動整個價值鏈的策略重組。開發人員正優先考慮產品組合的合理化，以突出更安全、循證性更強的產品；他們正積極建立跨行業夥伴關係，以加速開發非钆基造影劑；並加強與放射學網路的合作，以支持循證醫學證據的生成和應用。因此，該產業正從傳統的商品主導模式轉向差異化、實證主導的生態系統，在這個系統中，安全性、臨床結果和營運整合決定著長期的競爭優勢。

2025年，累積驅動的供應鏈重組和策略性製造決策將再形成整個MRI造影生態系統的採購、供應和營運韌性。

2025年累積關稅的實施，導致MRI造影劑生產商、經銷商和醫療服務提供者的供應鏈經濟和策略規劃發生了重大調整。為此，各公司不得不重新審視其原料藥、螯合劑和成品藥的籌資策略，尤其關注原料供應商和委託製造生產商的地理分佈。這種調整促使企業更加重視供應的安全性和韌性，從而轉向多元化的供應商網路和緊急庫存策略，以應對進口成本波動和運輸中斷的影響。

此外，關稅環境也影響外商投資和生產能力在地化的決策。一些公司正在評估在境內或近岸生產的優勢，以減輕進口關稅的影響並縮短醫院採購前置作業時間。建立國內生產需要遵守區域監管框架並通過生產流程檢驗，而這些因素與監管時間表和品質要求相互影響。從採購角度來看，醫院和影像中心正在重新談判合約並尋求定價機制，以降低關稅帶來的成本風險，而經銷商在調整其商業模式，以反映更高的到岸成本並保護其利潤結構。

此外，關稅背景促使人們更加關注能夠降低每位患者消費量量的製劑和給藥策略，包括最佳化給藥通訊協定和支持以較低劑量提供同等診斷價值的替代藥物。產業相關人員正加強與貿易和衛生當局的對話，以明確關稅分類，在合理情況下為重要的臨床藥物爭取豁免，並倡導可預測的貿易慣例，從而保障患者照護的連續性和持續創新。

明確產品化學性質、臨床應用、最終用途、分銷管道和給藥途徑如何相互交織，從而確定各細分市場的策略重點。

對細分市場的細緻分析闡明了產品特性、臨床應用案例和分銷管道如何相互作用，從而確定策略重點和商業化策略。根據產品類型，產品組合通常分為離子型和非離子型製劑。離子型產品主要包括钆基製劑，此類別進一步細分為鎖狀製劑和大環製劑，因為分子結構會顯著影響體內穩定性和安全性。非離子型產品涵蓋更廣泛的化學成分，包括钆基、鐵基和錳基製劑，非離子型钆製劑也根據其分子結構（如適用）按線性或大環結構進行分類。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 提高無钆奈米顆粒的臨床應用速率，以提升其安全性
  • 將人工智慧驅動的影像最佳化演算法整合到磁振造影對比通訊協定中
  • 增加對用於兒科磁振造影的可生物分解大環製劑的探索
  • 線性钆螯合物在新的安全資料公佈後，正受到更嚴格的監管審查。
  • 開發結合MRI造影劑和標靶藥物傳遞的多功能診療劑
  • 利用高弛豫性氧化鐵奈米顆粒改善老年患者的血管成像
  • 生技Start-Ups與影像中心建立策略夥伴關係，加速新型MRI藥物的核准。
  • 病人安全計劃和報銷政策變化推動了低劑量造影通訊協定需求的激增
  • 增加對器官特異性造影劑的投資，以最佳化區分肝臟和腎臟病變。
  • 雙模PET-MRI對比探針的出現可提高腫瘤診斷工作流程中的診斷準確性

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依產品類型分類的MRI造影劑市場

  • 離子
    • 钆基藥物
      • 線性藥物
      • 大環化合物
  • 非離子型
    • 钆基藥物
      • 線性藥物
      • 大環化合物
    • 鐵基藥物
    • 錳基藥物

9. 依藥物類別造影的MRI 造影劑市場

  • 钆基藥物
    • 線性藥物
    • 大環化合物
  • 鐵基藥物
  • 錳基藥物

第10章：按應用分類的MRI造影劑市場

  • 腹部影像檢查
    • 胃腸道影像檢查
    • 肝臟影像檢查
  • 心血管影像
    • 心臟影像
    • 血管影像
  • 中樞神經系統影像檢查
  • 肌肉骨骼影像

第11章：依最終用途分類的MRI造影劑市場

  • 門診手術中心
  • 診斷影像中心
  • 醫院
    • 社區醫院
    • 三級醫療機構
  • 研究所

第12章 MRI造影劑市場依通路分類

  • 直銷
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：依給藥途徑分類的MRI造影劑市場

  • 關節內給藥
  • 靜脈注射
  • 口服

第14章：按地區分類的MRI造影劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：按組別分類的MRI造影劑市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國MRI造影劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • GE HealthCare Technologies Inc.
    • Bracco Imaging SpA
    • Bayer AG
    • Guerbet SA
    • Lantheus Medical Imaging, Inc.
    • Mallinckrodt plc
    • Fujifilm Holdings Corporation
    • Daiichi Sankyo Company, Limited
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Sichuan Kelun Pharmaceutical Co., Ltd.
Product Code: MRR-F927BA46208C

The MRI Contrast Media Agents Market is projected to grow by USD 4.89 billion at a CAGR of 7.83% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.67 billion
Estimated Year [2025] USD 2.88 billion
Forecast Year [2032] USD 4.89 billion
CAGR (%) 7.83%

An authoritative orientation to MRI contrast media agents that frames chemical diversity, clinical utility, and safety imperatives shaping product development and clinical adoption

Magnetic resonance imaging contrast media agents are integral to modern diagnostic imaging, enhancing tissue contrast and enabling confident interpretation across a broad range of clinical indications. The landscape is chemically diverse, encompassing gadolinium-based agents historically dominant in many diagnostic workflows, alongside iron- and manganese-based alternatives engineered to address specific safety and imaging objectives. Beyond chemistry, formulation attributes such as ionic versus non-ionic character and molecular architecture-specifically linear versus macrocyclic chelation for gadolinium complexes-inform both clinical performance and safety profiles.

Clinical utility spans abdominal, cardiovascular, central nervous system, and musculoskeletal imaging, and these applications drive nuanced requirements for relaxivity, biodistribution, and clearance. Consequently, stakeholders must weigh diagnostic benefits against evolving safety evidence and regulatory guidance. Over recent years, concerns regarding gadolinium retention in tissues and the risk, albeit low, of nephrogenic systemic fibrosis in susceptible patients have catalyzed both innovation and reappraisal of prescribing patterns. Therefore, a contemporary introduction to contrast media must foreground not only pharmacological and physicochemical attributes, but also emerging clinical best practices, risk mitigation measures, and the regulatory environment shaping product availability and labeling.

This orientation sets the stage for strategic analysis: manufacturers, clinicians, and procurement leaders benefit from a clear understanding of how molecular design, administration route, and end-use setting converge to determine clinical adoption, safety monitoring, and commercial viability. As the diagnostic imaging ecosystem evolves, this foundational perspective enables stakeholders to anticipate shifts in product preference, investment priorities, and collaborative pathways across industry and healthcare delivery systems.

How safety scrutiny, imaging technology advances, and regulatory realignment are catalyzing a strategic transformation across MRI contrast agent innovation and adoption

The landscape for MRI contrast agents is undergoing transformative shifts driven by converging forces: heightened safety scrutiny, technological advances in imaging protocols, and a reconfigured regulatory and procurement environment. Safety concerns, particularly those related to gadolinium retention, have accelerated interest in macrocyclic chelates, which offer greater kinetic stability than linear counterparts and are increasingly positioned as preferred options in many clinical pathways. Meanwhile, innovation is expanding beyond gadolinium into iron- and manganese-based agents that aim to balance diagnostic performance with differentiated safety and pharmacokinetic properties.

Concurrently, improvements in MRI hardware and sequence design are altering contrast requirements; higher-field scanners, quantitative imaging biomarkers, and AI-enhanced post-processing can increase sensitivity and may reduce the reliance on high-dose contrast administrations. These technological advances encourage manufacturers and clinical teams to re-evaluate dosing strategies and to develop agents optimized for specific imaging paradigms. Regulatory agencies are responding with more granular guidance on labeling, risk communication, and post-market surveillance, prompting manufacturers to invest in longitudinal safety studies and to strengthen pharmacovigilance infrastructures.

From a commercial perspective, these shifts are prompting strategic realignments across the value chain. Organizations are prioritizing portfolio rationalization to emphasize safer, higher-evidence products, forging cross-sector partnerships to accelerate development of non-gadolinium agents, and enhancing engagement with radiology networks to support evidence generation and adoption. As a result, the sector is transitioning from a legacy, commodity-driven model toward a differentiated, evidence-led ecosystem in which safety, clinical outcomes, and operational integration determine long-term competitive advantage.

Cumulative tariff-driven supply chain recalibrations and strategic manufacturing decisions reshaping sourcing, procurement, and operational resilience across the MRI contrast ecosystem in 2025

The introduction of cumulative tariffs in 2025 has produced a material recalibration of supply chain economics and strategic planning across manufacturers, distributors, and healthcare providers dealing with MRI contrast agents. In response, organizations have had to re-examine sourcing strategies for APIs, chelating agents, and finished formulations, with particular attention to the geographic footprint of raw material suppliers and contract manufacturers. This recalibration has increased the emphasis on supply security and resilience, prompting a shift toward diversified supplier networks and contingency inventory strategies to buffer against import cost volatility and transport disruptions.

Furthermore, the tariff environment has influenced decisions about inward investment and the localization of manufacturing capacity. Some companies are evaluating the benefits of onshore or nearshore production to reduce exposure to import duties and to shorten lead times for hospital procurement cycles. These considerations interact with regulatory timelines and quality requirements, as establishing domestic manufacturing necessitates compliance with regional regulatory frameworks and validation of manufacturing processes. From a procurement perspective, hospitals and imaging centers are renegotiating contracts and seeking pricing mechanisms that mitigate tariff-driven cost exposure, while distributors are adjusting commercial models to reflect increased landed costs and to protect margin structures.

In addition, the tariff context has amplified interest in formulations and administration strategies that reduce per-patient product consumption, including optimizing dosage protocols and supporting alternatives that offer comparable diagnostic value at lower administered mass. Finally, this period has underscored the importance of policy engagement: industry players are intensifying dialogues with trade and health authorities to clarify tariff classifications, pursue exemptions where justified for critical clinical supplies, and advocate for predictable trade policies that support uninterrupted patient care and continued innovation.

Segment-based clarity revealing how product chemistry, clinical applications, end-use settings, distribution channels, and administration routes converge to drive strategic priorities

A granular view of segmentation clarifies how product features, clinical use cases, and distribution pathways interact to define strategic priorities and commercialization tactics. Based on product type, portfolios are commonly divided into ionic and non-ionic formulations. Ionic products predominantly include gadolinium-based agents, and within that category a further distinction is drawn between linear agents and macrocyclic agents because molecular architecture significantly influences in-vivo stability and safety perceptions. Non-ionic product lines encompass a broader chemistry set that includes gadolinium-based agents, iron-based agents, and manganese-based agents, with gadolinium within the non-ionic subset also categorized by linear and macrocyclic structure when applicable.

Based on agent class, the field is organized into gadolinium-based, iron-based, and manganese-based agents, where gadolinium options are again differentiated into linear and macrocyclic forms to reflect differences in chelation stability. Based on application, contrast agents are applied across abdominal imaging, cardiovascular imaging, central nervous system imaging, and musculoskeletal imaging; abdominal imaging itself is subdivided into gastrointestinal and liver imaging while cardiovascular imaging can be decomposed into cardiac and vascular imaging to align with distinct diagnostic protocols and dosing considerations.

Based on end use, the agents are deployed in settings ranging from ambulatory surgical centers and diagnostic imaging centers to hospitals and research institutes, with hospitals further classified into community hospitals and tertiary care centers to reflect variation in case complexity and purchasing behavior. Based on distribution channel, the market engages direct sales to institutional customers as well as hospital pharmacies, online pharmacies, and retail pharmacy channels that serve outpatient demand. Finally, based on administration route, agents are employed through intraarticular, intravenous, and oral administration pathways, each of which presents different formulation, delivery device, and clinical workflow requirements that manufacturers must address in product design and commercialization planning.

Region-specific regulatory, clinical, and supply considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption patterns and strategic positioning

Regional dynamics are a central determinant of product strategy, regulatory planning, and commercial execution, and they vary across major markets such as the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical networks and purchasing aggregates often emphasize evidence-led adoption and large-scale procurement agreements, which influence manufacturers to prioritize robust safety dossiers and streamlined logistics to support national and regional hospital systems. The United States regulatory environment and reimbursement structures in the region shape pricing and market entry strategies, while North American academic centers frequently lead clinical research that informs global guidelines.

Europe, Middle East & Africa presents a mosaic of regulatory frameworks and clinical practices where pan-regional harmonization efforts coexist with country-level variation. European regulatory authorities have been active on safety communication and post-market surveillance, prompting manufacturers to tailor pharmacovigilance and labeling across jurisdictions. In the Middle East and Africa, infrastructure constraints and regional procurement models create different adoption timelines, and stakeholders may prioritize cost-effective formulations and logistical simplicity when implementing contrast-enhanced imaging programs.

Asia-Pacific is characterized by rapid capacity expansion, diverse regulatory maturity, and strong manufacturing ecosystems for both API and finished products. Several markets in the region combine large patient volumes with growing diagnostic capabilities, encouraging local manufacturers and global companies to form partnerships and to invest in regional clinical evidence generation. Across these regions, strategic differentiation rests on aligning product attributes with local clinical practice, regulatory expectations, and distribution realities to optimize adoption and sustain supply continuity.

How incumbent pharmaceutical and specialty developers are pursuing evidence, supply integration, and partnerships to sustain competitive advantage in MRI contrast media

Competitive dynamics in the MRI contrast agent space are shaped by incumbent pharmaceutical and medical imaging companies, alongside nimble specialty developers advancing novel chemistries and targeted formulations. Established players focus on portfolio optimization, safety evidence generation, and scale efficiencies in manufacturing and distribution. These companies often invest in reformulations, new labeling claims, and targeted clinical studies to defend and reposition legacy products in a market increasingly attentive to retention risk and chelate stability. At the same time, smaller biotechnology firms and specialty pharmaceutical companies are advancing iron- and manganese-based agents that offer differentiated safety or functional imaging properties, driving partnerships and licensing activity as a pragmatic route to commercialization.

Strategic behaviors include vertical integration of supply chains to secure critical raw materials, collaboration with imaging device manufacturers to demonstrate product-device synergies, and selective geographic expansion guided by regulatory and clinical research priorities. In addition, there is an increasing focus on real-world evidence generation and health economics research to articulate value propositions for hospital procurement committees and payers. Distribution partners and specialty pharmacies are adapting commercial models to support complex logistics for contrast media that require cold chain management, controlled inventory oversight, and alignment with hospital formularies.

Taken together, these dynamics suggest that competitive advantage will accrue to organizations that can marry high-quality safety and efficacy evidence with reliable, flexible supply capabilities, and that can translate clinical differentiation into operational and economic benefits for healthcare providers.

Practical strategic actions for industry leaders to secure supply, strengthen safety evidence, and accelerate clinical adoption while mitigating tariff and regulatory risks

Leaders seeking to preserve and expand their position in the MRI contrast media domain should adopt a set of actionable strategies that emphasize safety, supply-chain resilience, and evidence-driven commercialization. First, prioritize investment in molecular designs and formulations with demonstrable stability and safety profiles, while advancing the clinical data necessary to support differentiated labeling and clinician confidence. Second, diversify procurement and manufacturing footprints to reduce exposure to tariff fluctuations and logistic disruptions, including evaluating nearshoring or qualified dual-sourcing for critical inputs.

Third, accelerate clinical and real-world evidence programs that directly address clinician concerns about retention and adverse events, and align these programs with regulatory reporting requirements to build trust with governing agencies. Fourth, develop commercial models that integrate with hospital formularies and imaging workflows, offering education, protocol optimization, and economic analyses to support adoption. Fifth, pursue strategic collaborations with imaging device manufacturers, academic research centers, and contract research organizations to expedite validation of agent-device synergies and to expand indications where appropriate. Finally, refine distribution strategies by blending direct sales to large institutional customers with pharmacy channel partnerships to reach outpatient markets, while ensuring rigorous cold chain and inventory controls.

By implementing these interlocking initiatives, organizations can reduce operational risk, strengthen clinical credibility, and create differentiated value propositions that resonate with radiologists, procurement leaders, and institutional payers.

A rigorous mixed-methods research approach integrating clinician interviews, regulatory review, and evidence triangulation to yield actionable strategic insight

The research underpinning this analysis combined primary qualitative engagement with domain experts, comprehensive review of regulatory and clinical literature, and triangulation against public clinical trial registries and patent filings. Primary inputs included structured interviews with practicing radiologists, pharmacovigilance specialists, hospital procurement leaders, and R&D executives to capture firsthand perspectives on clinical needs, adoption barriers, and supply chain priorities. Secondary sources encompassed regulatory communications, peer-reviewed safety and efficacy studies, and technical documentation relating to chelation chemistry and formulation approaches.

Methodologically, findings were synthesized through a layered approach: clinical insights were cross-referenced with regulatory trends to assess likely labeling and surveillance implications; manufacturing and distribution considerations were modeled qualitatively to identify resilience levers under tariff pressures; and competitive strategies were validated through analysis of corporate disclosures and partnership announcements. Emphasis was placed on extracting actionable implications rather than quantitative market sizing, and all conclusions were tested for plausibility against multiple independent sources to ensure robustness and relevance for decision-makers.

Synthesis of clinical, operational, and policy imperatives that define strategic pathways for resilient and patient-centric MRI contrast media portfolios

In conclusion, the MRI contrast media landscape is at an inflection point in which safety imperatives, technological advances, and external policy dynamics collectively shape near- and medium-term strategy. Stakeholders must balance the established diagnostic utility of gadolinium-based agents with the need to respond to retention concerns by prioritizing macrocyclic chemistries and advancing non-gadolinium alternatives where clinically appropriate. At the same time, the operational and commercial impacts of trade policy shifts necessitate a renewed focus on supply chain diversification and manufacturing flexibility to maintain uninterrupted patient care.

Looking ahead, organizations that invest in high-quality clinical evidence, engage proactively with regulators, and construct resilient distribution and production architectures will be better positioned to navigate evolving clinical preferences and procurement pressures. Collaboration across the value chain-including partnerships between specialty developers, established suppliers, imaging device firms, and healthcare providers-will accelerate the development and adoption of safer, more effective contrast solutions. Ultimately, strategic success will depend on integrating scientific rigor with operational adaptability to meet the diagnostic needs of clinicians while protecting patients and sustaining long-term commercial viability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing clinical adoption of gadolinium-free nanoparticles for enhanced safety profiles
  • 5.2. Integration of AI-driven image optimization algorithms in MR contrast protocols
  • 5.3. Rising research into biodegradable macrocyclic agents for pediatric MRI applications
  • 5.4. Regulatory scrutiny intensifying around linear gadolinium chelates following new safety data
  • 5.5. Development of multifunctional theranostic agents combining MRI contrast with targeted drug delivery
  • 5.6. Expansion of high-relaxivity iron oxide nanoparticles for improved vascular imaging in elderly patients
  • 5.7. Strategic collaborations between biotech startups and imaging centers to accelerate novel MRI agent approvals
  • 5.8. Surge in demand for low-dose contrast protocols driven by patient safety advocacy and reimbursement changes
  • 5.9. Growing investment in organ-specific contrast agents optimized for hepatic and renal lesion differentiation
  • 5.10. Emergence of dual-modal PET-MRI contrast probes enhancing diagnostic accuracy in oncology workflows

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. MRI Contrast Media Agents Market, by Product Type

  • 8.1. Ionic
    • 8.1.1. Gadolinium Based Agents
      • 8.1.1.1. Linear Agents
      • 8.1.1.2. Macrocyclic Agents
  • 8.2. Non Ionic
    • 8.2.1. Gadolinium Based Agents
      • 8.2.1.1. Linear Agents
      • 8.2.1.2. Macrocyclic Agents
    • 8.2.2. Iron Based Agents
    • 8.2.3. Manganese Based Agents

9. MRI Contrast Media Agents Market, by Agent Class

  • 9.1. Gadolinium Based Agents
    • 9.1.1. Linear Agents
    • 9.1.2. Macrocyclic Agents
  • 9.2. Iron Based Agents
  • 9.3. Manganese Based Agents

10. MRI Contrast Media Agents Market, by Application

  • 10.1. Abdominal Imaging
    • 10.1.1. Gastrointestinal Imaging
    • 10.1.2. Liver Imaging
  • 10.2. Cardiovascular Imaging
    • 10.2.1. Cardiac Imaging
    • 10.2.2. Vascular Imaging
  • 10.3. Central Nervous System Imaging
  • 10.4. Musculoskeletal Imaging

11. MRI Contrast Media Agents Market, by End Use

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Diagnostic Imaging Centers
  • 11.3. Hospitals
    • 11.3.1. Community Hospitals
    • 11.3.2. Tertiary Care Hospitals
  • 11.4. Research Institutes

12. MRI Contrast Media Agents Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. MRI Contrast Media Agents Market, by Administration Route

  • 13.1. Intraarticular Administration
  • 13.2. Intravenous Administration
  • 13.3. Oral Administration

14. MRI Contrast Media Agents Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. MRI Contrast Media Agents Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. MRI Contrast Media Agents Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. GE HealthCare Technologies Inc.
    • 17.3.2. Bracco Imaging S.p.A.
    • 17.3.3. Bayer AG
    • 17.3.4. Guerbet SA
    • 17.3.5. Lantheus Medical Imaging, Inc.
    • 17.3.6. Mallinckrodt plc
    • 17.3.7. Fujifilm Holdings Corporation
    • 17.3.8. Daiichi Sankyo Company, Limited
    • 17.3.9. Jiangsu Hengrui Medicine Co., Ltd.
    • 17.3.10. Sichuan Kelun Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. MRI CONTRAST MEDIA AGENTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. MRI CONTRAST MEDIA AGENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MRI CONTRAST MEDIA AGENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2032 (USD MILLION